136402-93-2

Usage

Uses

Used in Pharmaceutical Industry:
2-Methoxynaphthalen-1-ylmethylamine is used as an intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and medicines.
Used in Agrochemical Industry:
2-METHOXYNAPHTHALEN-1-YLMETHYLAMINE is also utilized as an intermediate in the production of agrochemicals, playing a role in the creation of substances that help protect and enhance crop yields.
Used in Organic Compounds Synthesis:
2-Methoxynaphthalen-1-ylmethylamine is used as a building block in the synthesis of various organic compounds for commercial and industrial applications, highlighting its versatility in chemical manufacturing processes.

Upstream product

• 5392-12-1 2-methoxy-1-naphthaldehyde 
• 408353-83-3 N-(2-methoxy-[1]naphthylmethyl)-benzamide 
• 93-04-9 2-Methoxynaphthalene 
• 64-17-5 ethanol 
• 99806-91-4 2‐methoxy‐1‐naphthaldoxime 

Downstream Products

• 408353-83-3 N-(2-methoxy-[1]naphthylmethyl)-benzamide 
• 67367-39-9 1-chloromethyl-2-methoxynaphthalene 
• 40696-22-8 (2-methoxy-naphthalene-1-yl)-methanol 
• 102237-71-8 (2-methoxy-benzylidene)-(2-methoxy-[1]naphthylmethyl)-amine 
• 103207-12-1 2-[(2-Methoxy-[1]naphthylmethylimino)-methyl]-phenol 

Relevant academic research and scientific papers

Arylalkylamine vanadium (V) salts for the treatment and/or prevention of Diabetes mellitus

This invention provides compounds of formula (IIA) and pharmaceutical compositions thereof, where M, a, b, and R1-R5 are as defined herein, for treating human type 1 and type 2 diabetes, particularly insulin-resistant diabetes. Pharmaceutical compositions comprising the compounds of formula (IIA) are also disclosed.

COMPOSITION OF SSAO SUBSTRATES AND METAL COMPOUNDS OF THE VLA AND VLB GROUPS OF THE PERIODIC TABLE

This invention relates to (pharmaceutical) compositions comprising a combination of SSAO substrates and pharmaceutically acceptable compounds of the Vla and Vlb group of the periodic table, i.e. selenium (VI)-, molybdenum (VI)- and tungsten (V)/(VI) compounds, etc. and to their use as insulin mimetic, i.e., to treat illness Diabetes mellitus, Obesity, or their symptoms. A here discovered synergism between the compounds of the Vla and Vlb groups of the periodic table, i.e. selenium (VI)-, molybdenum (VI)- and tungsten (V)/(VI) com-pounds, etc. and the SSAO substrates makes the effective concentration of the compounds of the Via and Vlb groups of the periodic table in the (pharmaceutical) composition one order of magnitude lower than the corresponding compound of the Vla and Vlb groups alone. Consequently the inventive (pharmaceutical) composition has much lower toxicity than the known compounds or compositions in the art alone, what is a crucial advantage of the former for its use in the treatment and/or prevention of Diabetes mellitus, particularly of Diabetes type 2, or Obesity.

ARYLALKYLAMINE VANADIUM (V) SALTS FOR THE TREATMENT AND/OR PREVENTION OF DIABETES MELLITUS

This invention provides compounds and pharmaceutical compositions thereof for treating human type 1 and type 2 diabetes, particularly insulin-resistant diabetes.